Previous Close | 14.72 |
Open | 14.52 |
Bid | 14.61 x 800 |
Ask | 14.62 x 800 |
Day's Range | 14.39 - 14.73 |
52 Week Range | 11.81 - 24.96 |
Volume | |
Avg. Volume | 671,477 |
Market Cap | 2.348B |
Beta (5Y Monthly) | 1.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.22 |
Earnings Date | Feb 28, 2024 - Mar 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.14 |
Subscribe to Yahoo Finance Plus to view Fair Value for CERT
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapiesPRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex novel and generic small molecule medicines quickly and cost effective
Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript November 8, 2023 Certara, Inc. reports earnings inline with expectations. Reported EPS is $0.11 EPS, expectations were $0.11. Operator: Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being […]